A phase 1 first in human study to investigate INV-441 in Glioblastoma
Latest Information Update: 16 Oct 2024
Price :
$35 *
At a glance
- Drugs INV 441 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- 16 Oct 2024 New trial record
- 15 Oct 2024 According to invIOs media release, pre-IND meeting with US FDA has been successfully completed. This planned to be conducted by the DFCI and is expected to initiate in mid-2025.